Details for Patent: 8,987,323

Which drugs does patent 8,987,323 protect, and when does it expire?

Patent 8,987,323 protects BRENZAVVY and is included in one NDA.

This patent has thirty-six patent family members in thirty countries.

Summary for Patent: 8,987,323

Patent landscape, scope, and claims:

Title:	Crystalline form of benzylbenzene SGLT2 inhibitor
Abstract:	Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Inventor(s):	Cai Mengzhuang, Liu Qian, Xu Ge, Lv Binhua, Seed Brian, Roberge Jacques Y.
Assignee:	Theracos, Inc.
Application Number:	US13158724
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 8,987,323

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,987,323

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	121997
Australia	2011264220
Brazil	112012031616
Canada	2800379